ITTO20040329A1 - Uso di una composizione farmaceutica per il trattamento di patologie derivate da infezione da herpes virus, papilloma virus,hepatitis virus, nevralgie di origine virale, displasie di origine virale, displasie di origine virale, forme virali per immun - Google Patents

Uso di una composizione farmaceutica per il trattamento di patologie derivate da infezione da herpes virus, papilloma virus,hepatitis virus, nevralgie di origine virale, displasie di origine virale, displasie di origine virale, forme virali per immun

Info

Publication number
ITTO20040329A1
ITTO20040329A1 IT000329A ITTO20040329A ITTO20040329A1 IT TO20040329 A1 ITTO20040329 A1 IT TO20040329A1 IT 000329 A IT000329 A IT 000329A IT TO20040329 A ITTO20040329 A IT TO20040329A IT TO20040329 A1 ITTO20040329 A1 IT TO20040329A1
Authority
IT
Italy
Prior art keywords
viral origin
dysplasia
viral
virus
diseases
Prior art date
Application number
IT000329A
Other languages
English (en)
Inventor
Franco Deraco
Original Assignee
Franco Deraco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Franco Deraco filed Critical Franco Deraco
Priority to IT000329A priority Critical patent/ITTO20040329A1/it
Publication of ITTO20040329A1 publication Critical patent/ITTO20040329A1/it
Priority to EP05010726A priority patent/EP1627663A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT000329A 2004-05-18 2004-05-18 Uso di una composizione farmaceutica per il trattamento di patologie derivate da infezione da herpes virus, papilloma virus,hepatitis virus, nevralgie di origine virale, displasie di origine virale, displasie di origine virale, forme virali per immun ITTO20040329A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT000329A ITTO20040329A1 (it) 2004-05-18 2004-05-18 Uso di una composizione farmaceutica per il trattamento di patologie derivate da infezione da herpes virus, papilloma virus,hepatitis virus, nevralgie di origine virale, displasie di origine virale, displasie di origine virale, forme virali per immun
EP05010726A EP1627663A3 (en) 2004-05-18 2005-05-18 Use of a pharmaceutical composition for the treatment of pathologies derived from infection by herpes virus, papillomavirus, hepatitis virus, viral neuralgia, viral dsyplasia, immune-deficiency-induced viral infections and viral neuritis.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000329A ITTO20040329A1 (it) 2004-05-18 2004-05-18 Uso di una composizione farmaceutica per il trattamento di patologie derivate da infezione da herpes virus, papilloma virus,hepatitis virus, nevralgie di origine virale, displasie di origine virale, displasie di origine virale, forme virali per immun

Publications (1)

Publication Number Publication Date
ITTO20040329A1 true ITTO20040329A1 (it) 2004-08-18

Family

ID=34936625

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000329A ITTO20040329A1 (it) 2004-05-18 2004-05-18 Uso di una composizione farmaceutica per il trattamento di patologie derivate da infezione da herpes virus, papilloma virus,hepatitis virus, nevralgie di origine virale, displasie di origine virale, displasie di origine virale, forme virali per immun

Country Status (2)

Country Link
EP (1) EP1627663A3 (it)
IT (1) ITTO20040329A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104784142A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种甲硫氨酸片的制备方法
CN104784141A (zh) * 2014-01-17 2015-07-22 南京瑞尔医药有限公司 一种甲硫氨酸片组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
CA2078019C (en) * 1991-09-13 2002-08-27 Siegbert Heinrich Bissbort Substance or composition and uses thereof
CN1213747C (zh) * 2000-03-03 2005-08-10 李叔文 爱滋病特效药

Also Published As

Publication number Publication date
EP1627663A2 (en) 2006-02-22
EP1627663A3 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
JP2009511595A5 (it)
IL164729A0 (en) Nucleoside derivatives for treating hepatitis c virus infection
PL376043A1 (en) Nucleoside derivatives for treating hepatitis c virus infection
DK1644037T3 (da) Funktionell infulenza-virus-lignende partikler (VLP'er)
CY1114892T1 (el) Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση
CY1111552T1 (el) Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
FR15C0084I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
PT1299395E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
EP2120988A4 (en) TREATMENT OF HEPATITIS C VIRUS INFECTIONS
SV2005001919A (es) Compuestos nucleosidos para el tratamiento de infecciones virales
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
JP2006507295A5 (it)
AU2003279551A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
ITTO20040329A1 (it) Uso di una composizione farmaceutica per il trattamento di patologie derivate da infezione da herpes virus, papilloma virus,hepatitis virus, nevralgie di origine virale, displasie di origine virale, displasie di origine virale, forme virali per immun
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus
CU23031A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
IS6184A (is) Bóluefni gegn ISA veiru
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators